Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wendy Stock

Showing results (91-100 of 322) with videos related to

Pageof 33
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 19, 2004
Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphomaKoen Van Besien, Rakesh Mehra, Navin Wadehra, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 8, 2009
BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplantsPeter H O'Donnell, Kate Swanson, Michelle A Josephson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignanciesDavid A Rizzieri, Eric Feldman, John F Dipersio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2004
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignanciesTodd M Zimmerman, Helena Harlin, Olatoyosi M Odenike, et al.
Blood Cancer Journal|March 4, 2021
OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemiaBartholomew J Eisfelder, Caner Saygin, Joseph Wynne, et al.
Leukemia Research|August 5, 2014
Genomic aberrations in myeloid sarcoma without blood or bone marrow involvement: characterization of formalin-fixed paraffin-embedded samples by chromosomal microarraysM Kamran Mirza, Madina Sukhanova, Friedrich Stölzel, et al.
Leukemia Research|October 16, 2015
Targeting bone marrow lymphoid niches in acute lymphoblastic leukemiaGeoffrey L Uy, Yen-Michael S Hsu, Amy P Schmidt, et al.
Leukemia & Lymphoma|October 14, 2009
Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrenceKoen van Besien, Alexander Dew, Shang Lin, et al.
Chest|September 12, 2017
De Novo Development of Bronchiectasis in Patients With Hematologic MalignancyLena W Chen, Pamela J McShane, William Karkowsky, et al.
Leukemia & Lymphoma|April 15, 2003
Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013Richard T Silver, Bercedis L Peterson, Ted P Szatrowski, et al.
Pageof 33

Showing results (91-100 of 322) with videos related to

Sort By:
Pageof 33
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 19, 2004
Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphomaKoen Van Besien, Rakesh Mehra, Navin Wadehra, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 8, 2009
BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplantsPeter H O'Donnell, Kate Swanson, Michelle A Josephson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignanciesDavid A Rizzieri, Eric Feldman, John F Dipersio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2004
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignanciesTodd M Zimmerman, Helena Harlin, Olatoyosi M Odenike, et al.
Blood Cancer Journal|March 4, 2021
OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemiaBartholomew J Eisfelder, Caner Saygin, Joseph Wynne, et al.
Leukemia Research|August 5, 2014
Genomic aberrations in myeloid sarcoma without blood or bone marrow involvement: characterization of formalin-fixed paraffin-embedded samples by chromosomal microarraysM Kamran Mirza, Madina Sukhanova, Friedrich Stölzel, et al.
Leukemia Research|October 16, 2015
Targeting bone marrow lymphoid niches in acute lymphoblastic leukemiaGeoffrey L Uy, Yen-Michael S Hsu, Amy P Schmidt, et al.
Leukemia & Lymphoma|October 14, 2009
Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrenceKoen van Besien, Alexander Dew, Shang Lin, et al.
Chest|September 12, 2017
De Novo Development of Bronchiectasis in Patients With Hematologic MalignancyLena W Chen, Pamela J McShane, William Karkowsky, et al.
Leukemia & Lymphoma|April 15, 2003
Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013Richard T Silver, Bercedis L Peterson, Ted P Szatrowski, et al.
Pageof 33